Rank #1483PRLD

Prelude Therapeutics Incorporat

$2.27

5.58% (Daily)

Market Cap

$142.70M

Revenue

$10.50M

Rank by MCap

#1483

Sector

Healthcare

Industry

Biotechnology

CEO

Dr. Krishna Vaddi D.V.M., Ph.D.

Headquarters

Wilmington, DE

Employees

131

About Prelude Therapeutics Incorporat

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT3789, a selective degrader of SMARCA2 protein for the treatment of advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion; PRT7732, a selective and orally bioavailable SMARCA2 degraders to treat advanced or metastatic solid tumors; and PRT2527, a cyc...